melanoma

[Merck, Inc.] Merck announced that the US FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.

[Journal of Natural Products] Physachenolide C is a 17β-hydroxywithanolide natural product with a unique anticancer potential, as it exhibits potent and selective in vitro antiproliferative activity against prostate cancer (PC) cells. Researchers explored the effect of ring A/B modifications of physachenolide C on these biological activities.

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[Cancer Cell International] Data from 471 skin cutaneous melanoma patients in the The Cancer Genome Atlas were analyzed using ESTIMATE algorithms to generate an ImmuneScore, StromalScore, and EstimateScore for each patient.

[Histochemistry and Cell Biology] Scientists focused on potential differences in the activity of exosomes produced by melanoma cells towards melanoma-associated fibroblasts and normal dermal fibroblasts. They demonstrated that melanoma-produced exosomes significantly stimulated the tumor-promoting proinflammatory activity of cancer-associated fibroblasts.

[Translational Oncology] Three patient-derived cancer cells (PDCs) were established from NRAS Q61-positive metastatic melanoma patients. The response of PDCs and five established melanoma cell lines was evaluated toward a panel of 527 oncology drugs using high-throughput drug sensitivity and resistance testing.